Aura Biosciences to Repurchase 10.8% Stake from Matrix Capital at Discounted Price, Updates Cash
AURA sits 93% above its 52-week low of $4.345 on elevated volume (6.0× avg).
Summary
Aura Biosciences announced a definitive agreement to repurchase approximately 10.8% of its outstanding common stock from Matrix Capital Management at $5.64 per share, contingent on its new equity offering, and provided a preliminary cash balance of $114.7 million.
Key Events · Financing and Capital Events · AURA
-
Major Share Repurchase Agreement
Aura Biosciences will repurchase up to 6,922,870 shares, representing approximately 10.8% of its outstanding common stock, from Matrix Capital Management.
-
Discounted Repurchase Price
The shares will be repurchased at $5.64 per share, which is the price of the concurrently announced equity offering and a significant discount to the current market price of $8.39.
-
Funding from Equity Offering
The repurchase is contingent on and will be funded by net proceeds from the company's new underwritten equity offering that exceed $200 million.
-
Preliminary Cash Update
The company reported preliminary cash, cash equivalents, and marketable securities of approximately $114.7 million as of March 31, 2026.
Analysis · AURA · Life Sciences
This filing details a significant strategic move by Aura Biosciences to repurchase a substantial block of shares from a major institutional investor, Matrix Capital, at a price significantly below the current market value. While the repurchase is contingent on a new dilutive equity offering, the company is effectively using a portion of the new capital to manage its cap table and potentially remove an overhang from a large shareholder. The repurchase at a discount to the current trading price is favorable for the company. Additionally, the preliminary cash update provides a clearer picture of the company's liquidity, which is crucial given its prior "going concern" warning. This indicates active capital management and an improved near-term financial position.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AURA was trading at $8.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $536.1M. The 52-week trading range was $4.35 to $8.49. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.